三諾生物(300298.SZ):公司產品整體毛利率保持在60%左右
格隆匯7月13日丨三諾生物(300298.SZ)近期在接待機構投資者調研時表示,公司產品整體毛利率保持在60%左右。公司產品能保持較高毛利率的主要原因:(1)產品生產規模大且穩定,公司及全資和參股子公司在全球建立了8大生產基地,形成了以研發、採購、生產、質控、客服、質保等部門緊密銜接的質量管理體系,並保持其有效運轉和不斷完善,可以滿足全球市場需求;(2)自動化程度高,公司持續推動智能製造建設,從自動化、信息化、智能技術以及數智化轉型等多方面推進,生產線自動化率超過90%,產品生產成本低;(3)高度重視對產品研發的投入和自身研發綜合實力的提升,針對行業發展趨勢,公司持續對現有產品線升級,同時積極做好新產品的研發和技術儲備工作,產品的市場認可度較高,在糖尿病及相關慢病檢測領域已成為全球領先的企業。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.